The Prediction of Preeclampsia/Toxemia in Twin Pregnancy

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by Assaf-Harofeh Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier:
NCT01255202
First received: December 5, 2010
Last updated: December 6, 2010
Last verified: December 2010
  Purpose

The purpose of this study is to finout whetere uterinae artery flow , PP13 and endogolin levels in the serum and kongo red in the urine can predict preeclamsia toxemia in twin pregnancies.


Condition
Preeclampsia/Toxemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective Longitudenal Study in the Prediction of Preeclampsia/Toxemia in Twin Pregnancy

Resource links provided by NLM:


Further study details as provided by Assaf-Harofeh Medical Center:

Biospecimen Retention:   Samples Without DNA

serum and urine


Estimated Enrollment: 200
Study Start Date: September 2009
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
twin preganacies

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

women with twin preganacy undergoing nuchal scan in our department

Criteria

Inclusion Criteria:

  • a women with a vaiable twin pregnany

Exclusion Criteria:

  • women with thrombophilya
  • women terated with anticoagolant
  • women with vascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01255202

Contacts
Contact: Ran Svirsky, MD 972-8-9779000 rsvirs@gmail.com

Locations
Israel
Assaf Harofe Medical Center Recruiting
Zrifin, Israel
Contact: Ran Svirsky, MD    972-8-9779000    rsvirs@gmail.com   
Principal Investigator: Ran Svirsky, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center
  More Information

No publications provided

Responsible Party: Svirsky Ran, Assaf-Harofeh Medical Center
ClinicalTrials.gov Identifier: NCT01255202     History of Changes
Other Study ID Numbers: 189/09
Study First Received: December 5, 2010
Last Updated: December 6, 2010
Health Authority: Israel: Ethics Commission

Keywords provided by Assaf-Harofeh Medical Center:
preeclampsia
toxemia
twin
pregnancy
pp13
prediction
kongo red

Additional relevant MeSH terms:
Pre-Eclampsia
Toxemia
Sepsis
Hypertension, Pregnancy-Induced
Pregnancy Complications
Infection
Systemic Inflammatory Response Syndrome
Inflammation
Pathologic Processes

ClinicalTrials.gov processed this record on September 30, 2014